Magnetic Resonance Imaging to Evaluate Prostate Cancer
NCT00182624 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 80
Last updated 2017-07-02
Summary
This study will determine whether scanning the prostate using special magnetic resonance imaging (MRI) techniques can detect prostate cancers with greater accuracy than other methods. MRI uses a strong magnet and radio waves to produce images of body tissues. Unlike many cancers, prostate cancer is difficult to see on most imaging studies like x-rays, computed tomography (CT) scans, and conventional MRI scans. This study will use a magnet twice as strong as the magnets commonly used in MRI tests.
Patients 18 years of age and older with prostate cancer confirmed by prostate biopsy may be eligible for this study. Candidates are screened with a medical history, physical examination, and review of pathology reports.
Participants undergo MRI of the prostate and possibly a biopsy of the prostate gland, as follows:
Prostate MRI
Before coming to the NIH Clinical Center for the biopsy, patients take a Fleets enema to empty the rectum of fecal matter. For the MRI, an endorectal coil (a tube containing a specially designed antenna) is placed in the rectum, which is just behind the prostate. The coil increases the amount of signal received by the MRI unit. Additional coils may be wrapped around the pelvis to further improve the quality of the scan. The patient lies on a stretcher that moves into the scanner. A catheter (plastic tube) is placed in an arm vein for injection of a contrast agent called gadolinium, which brightens the images. Patients may also be asked to breathe an oxygen-rich gas through a mask during the scan to test the use of oxygen as a contrast agent in MRI. Patients may be asked to repeat the MRI to test the reproducibility of the procedure. The repeat test is optional.
Prostate Biopsy
Depending on the MRI findings, patients may be asked to undergo a prostate biopsy to obtain a sample of tumor tissue. The tissue is obtained with a needle placed through the rectum. Medicines may be used to reduce pain during the biopsy and to reduce the chance of infection.
Conditions
- Prostatic Neoplasms
Sponsors & Collaborators
-
National Institutes of Health Clinical Center (CC)
lead NIH
Eligibility
- Min Age
- 18 Years
- Sex
- MALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2004-02-02
- Completion
- 2007-09-06
Countries
- United States
Study Locations
More Related Trials
-
MRI/MRSI in Risk Assessment of Prostate Cancer Patients
NCT00582543 ·Status: COMPLETED ·Phase: NA
-
Multiparametric Magnetic Resonance Imaging of the Prostate to Assess Disease Progression and Genomics in Patients Undergoing Active Surveillance for Prostate Cancer
NCT04692675 ·Status: RECRUITING ·Phase: NA
-
Magnetic Resonance Imaging and Magnetic Resonance Spectroscopic Imaging in Diagnosing the Extent of Disease in Patients With Prostate Cancer
NCT00032058 ·Status: COMPLETED ·Phase: NA
-
Magnetic Resonance-Guided High-Dose Brachytherapy (Short-Range Radiation Therapy) for Prostate Cancer
NCT00039624 ·Status: COMPLETED ·Phase: PHASE2
-
Use of PET/MRI Tracer to Further Understanding of Prostate Cancer Development
NCT02106416 ·Status: COMPLETED ·Phase: NA
-
18F-PSMA PET and MRI in the Primary Staging of Prostate Cancer Patients
NCT05141760 ·Status: COMPLETED ·Phase: PHASE2
-
Contrast Enhanced MRI of the Prostate
NCT02245282 ·Status: COMPLETED
-
MRI Screening in Men at High Risk of Developing Prostate Cancer
NCT05608694 ·Status: RECRUITING ·Phase: NA
-
18F-DCFPyL PSMA- Versus 18F-NaF-PET Imaging for Detection of Metastatic Prostate Cancer
NCT03173924 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Correlation of Imaging Findings With Clinical Findings and Patient Outcomes in Prostate Cancer
NCT03122470 ·Status: WITHDRAWN ·Phase: NA
-
Using Magnetic Resonance Imaging (MRI) to Guide Differential-Dose Prostate Brachytherapy
NCT01913197 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
PSMA-PET/MRI Unfavorable-Risk Target Volume Pilot Study
NCT04176497 ·Status: TERMINATED ·Phase: PHASE2
-
MRI in Diagnosing Prostate Cancer
NCT01292291 ·Status: UNKNOWN ·Phase: NA
-
Evaluation of Treatment Response Using Multiparametric MRI After Prostate Radiotherapy
NCT02312401 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Role of Magnetic Resonance Imaging (MRI) Perfusion to Detect Disease in Prostate Carcinoma
NCT00230386 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Comparison Of DIR-MRI And DCE-MRI In Detection Of Prostate Cancer: A Pilot Study
NCT02939456 ·Status: COMPLETED ·Phase: NA
-
Incorporating MR Imaging Into Prostate Radiotherapy Treatment Planning
NCT02470910 ·Status: COMPLETED ·Phase: NA
-
Magnetic Resonance Imaging and Spectroscopy of the Prostate
NCT00590993 ·Status: COMPLETED
-
MRI Guided Prostate Biopsy
NCT06302595 ·Status: RECRUITING ·Phase: NA
-
PCMRI - an MRI/TRUS System for the Evaluation of the Prostate
NCT00542100 ·Status: UNKNOWN ·Phase: NA
-
Defining the Extent and Grade of Prostate Cancer Using Dynamic Contrast Enhanced Diffusion Weighted and BOLD MRI
NCT00242112 ·Status: COMPLETED ·Phase: NA
-
Magnetic Resonance Spectroscopic Imaging of the Prostate at 3 Tesla
NCT00588679 ·Status: COMPLETED ·Phase: NA
-
Intensity Modulated Radiation Therapy for Prostate Cancer
NCT00214422 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Characterization of Prostate Cancer With 3T MR
NCT00831142 ·Status: ACTIVE_NOT_RECRUITING
-
Detection of Clinically Significant Prostate Cancer With 18F-DCFPyL PET/MR
NCT03149861 ·Status: COMPLETED ·Phase: NA